Skip to content

Study · Not a test of the peptide alone · 2026

9 results

Copper nanoregulator with organelle-level precision reprograms COMMD1-Mediated copper homeostasis for myocardial infarction repair.

Zang Q, Qin Z, Ou J, Wang M, Zhou L, Zhou J, Yang X, Shen R, Wang K, Luo Y, Wu H, Mou J and 5 more

Show all authors

Wu J, Cai X, Du W, Zheng Y, Li Y

Biomaterials2 Jun 2026

PMID42258904 (opens in a new tab)DOI10.1016/j.biomaterials.2026.124362 (opens in a new tab)PepBankPUB-42258904
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Pharmacokinetics

    In a mouse myocardial infarction model, Qu@Cu-SS31 accumulated preferentially in infarcted regions.

    In plain wordsIn mice with heart attack, a copper-quercetin nanoregulator carrying SS31 collected mainly in the damaged heart area.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseAccumulation in infarcted regions
    Study

    mousen: not reported in source

    myocardial infarction
    Outcome group
    Pharmacokinetics · Cardiovascular

    Source sentences

    Summary
    Qu@Cu-SS31 exhibited preferential accumulation in infarcted regions, leading to significant functional recovery, reduced infarct size, and enhanced tissue regeneration.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  2. 02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In a mouse myocardial infarction model, Qu@Cu-SS31 led to significant functional recovery.

    In plain wordsIn mice with heart attack, a copper-quercetin nanoregulator carrying SS31 improved heart function.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseFunctional recovery
    Study

    mousen: not reported in source

    myocardial infarction
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    leading to significant functional recovery, reduced infarct size, and enhanced tissue regeneration.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  3. 03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In a mouse myocardial infarction model, Qu@Cu-SS31 reduced infarct size.

    In plain wordsIn mice with heart attack, a copper-quercetin nanoregulator carrying SS31 shrank the damaged heart area.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseInfarct size
    Study

    mousen: not reported in source

    myocardial infarction
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    reduced infarct size, and enhanced tissue regeneration.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  4. 04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In a mouse myocardial infarction model, Qu@Cu-SS31 enhanced tissue regeneration.

    In plain wordsIn mice with heart attack, a copper-quercetin nanoregulator carrying SS31 improved heart tissue regrowth.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseTissue regeneration
    Study

    mousen: not reported in source

    myocardial infarction
    Outcome group
    Wound healing · Cardiovascular

    Source sentences

    Summary
    enhanced tissue regeneration.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  5. 05LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism

    The copper-quercetin-SS31 nanoregulator Qu@Cu-SS31 significantly downregulated COMMD1.

    In plain wordsIn lab tests, a copper-quercetin nanoregulator carrying SS31 lowered COMMD1, a regulator of copper balance.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCOMMD1 expression
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    Qu@Cu-SS31 mediated significant downregulation of COMMD1, concomitant with downregulation of Cu transporters CTR1 and CCS.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  6. 06LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism

    Qu@Cu-SS31 downregulated the copper transporters CTR1 and CCS.

    In plain wordsIn lab tests, a copper-quercetin nanoregulator carrying SS31 lowered the copper transporters CTR1 and CCS.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCopper transporters CTR1 and CCS
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    concomitant with downregulation of Cu transporters CTR1 and CCS.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  7. 07LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome

    Qu@Cu-SS31 showed robust reactive oxygen species scavenging ability.

    In plain wordsIn lab tests, a copper-quercetin nanoregulator carrying SS31 cleared reactive oxygen species well.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseReactive oxygen species
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Cardiovascular

    Source sentences

    Summary
    Additionally, Qu@Cu-SS31 showed robust reactive oxygen species scavenging ability.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  8. 08LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism

    The COMMD1-Cu-ROS axis regulated by Qu@Cu-SS31 inhibited NLRP3-Caspase-1 dependent pyroptosis.

    In plain wordsIn lab tests, a copper-quercetin nanoregulator carrying SS31 blocked a form of inflammatory cell death called pyroptosis.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseNLRP3-Caspase-1 dependent pyroptosis
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Cardiovascular

    Source sentences

    Summary
    This COMMD1-Cu-ROS regulatory axis potently inhibited NLRP3-Caspase-1 dependent pyroptosis, and apoptosis via rebalance of Bcl-2/Bax expression.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  9. 09LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism

    The COMMD1-Cu-ROS axis regulated by Qu@Cu-SS31 inhibited apoptosis through rebalancing Bcl-2/Bax expression.

    In plain wordsIn lab tests, a copper-quercetin nanoregulator carrying SS31 reduced apoptosis by rebalancing Bcl-2 and Bax.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseApoptosis via Bcl-2/Bax rebalance
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Cardiovascular

    Source sentences

    Summary
    apoptosis via rebalance of Bcl-2/Bax expression.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.